Department of Internal Medicine I, Rheinische Friedrich Wilhelms Universität Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany
![]() |
Abstract |
---|
![]() ![]() ![]() |
---|
Keywords: HCV, T lymphocytes, mutations
CC-chemokines constitute a structurally related group of chemotactic cytokines which attract and activate specific subsets of inflammatory cells such as monocytes and T lymphocytes to the sites of infection. CC-chemokines bind to specific G-protein coupled receptors to trigger cell activation and migration. In particular, the CC-chemokines CCL3 (macrophagic inflammatory protein 1, MIP-1
), CCL4 (macrophagic inflammatory protein 1ß, MIP-1ß) and CCL5 (regulated upon activation, normal T cell expressed and secreted, RANTES) are ligands for the CC-chemokine receptor 5 (CCR5) and attract monocytes and T lymphocytes. Expression of the various different chemokine receptors and tissue specific migration is related to the state of differentiation and activation of inflammatory cells. Whereas naive T lymphocytes express chemokine receptor CXCR4, T helper (Th) cells producing type 1 cytokines such as interferon-
and tumour necrosis factor as well as a major subset of CD8+ cytotoxic T lymphocytes predominantly express CCR5.13 In contrast, lymphocytes secreting type 2 cytokines are characterized by expression of CCR3, CCR4 and CCR8. Intrahepatic infiltration of mononuclear inflammatory cells is the histological hallmark of hepatitis C virus (HCV) infection. Importantly, lymphocytes infiltrating HCV infected livers express high levels of CCR5 suggesting that Th1 driven immune responses are critically involved in the antiviral immune response of the host.4 Likewise, CCL3, CCL4 and CCL5 are expressed by vascular endothelial cells within portal tracts as well as by CD8+ cytotoxic T lymphocytes in the infiltrates.4
There is accumulating evidence that strong antiviral type 1 immune responses are associated with viral clearance both during the acute phase of primary HCV infection and antiviral therapy of chronic hepatitis C.57 On the other hand, CCR5+ T lymphocytes may also contribute to immune-mediated tissue damage of chronic hepatitis C.8,9 Unlike lymphocytes in infected livers, CCR5 expression is significantly reduced on CD4+ and CD8+ T lymphocytes in the peripheral blood.4,10 While this finding may just reflect selective compartmentalization of CCR5+ T cells to the liver, there is recent evidence suggesting that hepatitis C can counteract recruitment of antiviral CCR5+ T lymphocytes by down-regulating CCR5 expression via direct interactions of the HCV E2 envelope protein with the tetraspanin CD81.11 Furthermore HCV proteins such as HCV core and NS5A can modify CCL5 secretion by altering CCL5 promoter activity.12 Increased binding of CCL5 to its receptor CCR5 further decreases CCR5 surface density due to receptor internalization.13
Down-regulation of CCR5 might have important consequences for the hosts immune defence. Early after HCV infection, prominent CD8 cell responses are observed involving transient up-regulation of CCR5 expression.14 In chronic hepatitis C infection, however, CD8+ T lymphocytes show sustained dysfunction with poor type 1 cytokine secretion in response to HCV antigens and reduced expression of CCR5.14,15 Decreased CCR5 expression in chronic hepatitis C infection might correspond to diminished lymphocellular type 1 cytokine responses reported by several groups.15,16 Type 2 responses, however, are apparently preserved. Moreover, recruitment of CD8 cells into the liver might become more ineffective the more CCR5 expression is down-regulated. Of interest, sequential liver biopsies in patients with hepatitis C infection demonstrated steadily declining numbers of intrahepatic CD8 cells over the course of chronic infection.17 Thus, interfering with CCR5 mediated signalling may be part of the viral strategy to establish itself as chronic infection.
The CCR5 gene is subject to several mutations affecting its expression. Among these a 32 base pair deletion in the CCR5 open reading frame, CCR5-32, has gained major scientific interest, as it leads to a frameshift and prevents expression of a functional CCR5 protein.18 CCR5-
32 has a 9.2% allele frequency in Caucasians but is virtually absent in populations of non-Caucasian descent. Because CCR5 is an essential co-receptor for m-tropic human immunodeficiency virus (HIV) strains,19 subjects homozygous for the CCR5-
32 allele, who comprise approximately 1.1% in a Caucasian population,18 are almost completely protected against HIV infection. Furthermore, HIV progression seems to be delayed in CCR5-
32 heterozygous patients.20 Beyond that, altered expression due to the CCR5-
32 mutation should also affect CCR5-mediated pathways in the immune response against other infectious agents. This hypothesis is supported by studies in CCR5 knockout mice, which demonstrated a shift towards type 2 cytokine activation in a model of experimental colitis.21 Furthermore, such CCR5 knockout animals show subtle impairment of macrophage functions, T cell-dependent immune responses and reduced clearance of the intracellular pathogen Listeria monocytogenes.22 More importantly, CCR5-
32 has been proposed to affect the natural course of several human diseases which are putatively associated with a change in the balance between type 1 and type 2 cytokines as part of their pathogenesis (Table 1). Consequently, the concept that type 1 immune responses are critical for the inflammatory reaction and the antiviral immune defence in HCV infection prompts the hypothesis that reduced CCR5 expression due to the CCR5-
32 mutation might also affect susceptibility to chronic hepatitis C, its natural course and the outcome of antiviral therapy.
|
A possible role of the RANTES/CCR5 pathway in the pathogenesis of chronic HCV infection is further supported by histological studies. Although increased susceptibility to chronic HCV infection was also not observed in a large casecontrol study involving HCV-infected participants recruited from several centres across Europe, it identified the 403 polymorphism in the promoter region of CCL5 (RANTES) gene and CCR5-32 allele as the only mutations among 20 tested polymorphisms of chemokines and chemokine receptors to be significantly associated with reduced hepatic inflammation.29 Moreover, decreased interface hepatitis, lobular necrosis and portal inflammation have been observed in CCR5-
32 heterozygous Israeli patients with chronic hepatitis C of Ashkenazi and Sephardim descent.30 Both observations provide further support for the involvement of CCR5 and its ligand CCL5 in the pathogenesis of chronic hepatitis C. However, reports on potential effects of CCR5-
32 concerning fibrosis progression remain controversial.
It nevertheless remains a most important issue to clarify whether mutations of the CCR5 gene affect treatment outcomes in chronic hepatitis C. Type 1 interferons and ribavirin are the standard treatment options for chronic hepatitis C. Interferon exerts direct antiviral, anti-proliferative and immunomodulatory effects. Although its precise mechanism of action against hepatitis C virus infection is still poorly understood, Yang et al.31 have reported that interferon mediates immune activation at least partially via up-regulating CCR5 expression on CD4 and CD8 cells. With respect to ribavirin, the mode of action is even less clear. Nevertheless, it has been proposed that this nucleoside analogue can mediate immunomodulation by altering the type 1/type 2 cytokine bias towards more favourable type 1 immune responses.32,33 In line with the proposed mode of action, HCV-infected carriers of the CCR5-32 mutation showed significantly decreased response rates of viral elimination than wild-type patients in interferon monotherapy.34 In contrast, combination treatment with ribavirin consistently did not reveal any effects of CCR5-
32 on treatment outcomes.3436 Importantly, CCR5-
32 carriers with chronic HCV infection who had not responded to interferon monotherapy showed unusually high response rates when they were retreated with the interferon/ribavirin combination regimen. Thus, the addition of ribavirin seems to compensate for the negative effect of the CCR5-
32 mutation on treatment outcome. In this context, it is an intriguing speculation, that ribavirin might counteract the effects of CCR5-
32 by strengthening type 1 immune responses. Fortunately, combination treatment has meanwhile become the gold standard of anti-HCV therapy. Thus, CCR5-
32 has only little relevance with respect to current clinical practice in chronic HCV infection. However, this mutation may gain considerable importance for further therapeutic developments, because CCR5 inhibitors are currently being developed for the treatment of HIV infection and should be carefully checked in patients with HCV coinfection to avoid undesired side effects.
Taken together, there exist intriguing theoretical concepts as well as first observational evidence to suggest an important role of CCR5 and its ligands with respect to the pathogenesis of HCV infection. However, the available observational data remain controversial at the present stage. Further research in different ethnic populations and consideration of additional genetic markers are needed to understand the role of polymorphic genetic traits in a disease that is of polygenic nature. Furthermore, chronic hepatitis C virus infection may be just a first example for a group of infectious diseases, where alterations in the balance between type 1 and type 2 immune responses may be of importance. Therefore, it should also be worthwhile studying the potential roles of CCR5 and its ligands in other infectious diseases with a putatively altered immune balance such as tuberculosis and leprosy.
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() |
---|
2
.
Luster, A. D. (1998). Chemokineschemotactic cytokines that mediate inflammation. New England Journal of Medicine 338, 43645.
3
.
Qin, S., Rottman, J. B., Myers, P. et al. (1998). The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. Journal of Clinical Investigation 101, 74654.
4
.
Shields, P. L., Morland, C. M., Salmon, M. et al. (1999). Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 163, 623643.
5 . Cramp, M. E., Rossol, S., Chokshi, S. et al. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118, 34655.[ISI][Medline]
6 . Diepolder, H. M., Zachoval, R., Hoffmann, R. M. et al. (1995). Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346, 10067.[ISI][Medline]
7
.
Missale, G., Bertoni, R., Lamonaca, V. et al. (1996). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. Journal of Clinical Investigation 98, 70614.
8 . Apolinario, A., Majano, P. L., Alvarez-Perez, E. et al. (2002). Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. American Journal of Gastroenterology 97, 286170.[CrossRef][ISI][Medline]
9 . Boisvert, J., Kunkel, E. J., Campbell, J. J. et al. (2003). Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. Journal of Hepatology 38, 6775.[Medline]
10 . Lichterfeld, M., Leifeld, L., Nischalke, H. D. et al. (2002). Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. Journal of Infectious Diseases 185, 18037.[CrossRef][ISI][Medline]
11 . Nattermann, J., Nischalke, H. D., Feldmann, G. et al. (2004). Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. Journal of Viral Hepatitis, in press.
12 . Soo, H. M., Garzino-Demo, A., Hong, W. et al. (2002). Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 303, 25377.[CrossRef][ISI][Medline]
13
.
Solari, R., Offord, R. E., Remy, S. et al. (1997). Receptor-mediated endocytosis of CC-chemokines. Journal of Biological Chemistry 272, 961720.
14
.
Gruener, N. H., Lechner, F., Jung, M. C. et al. (2001). Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. Journal of Virology 75, 55508.
15 . Lechner, F., Gruener, N. H., Urbani, S. et al. (2000). CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. European Journal of Immunology 30, 247987.[CrossRef][ISI][Medline]
16 . Woitas, R. P., Lechmann, M., Jung, G. et al. (1997). CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. Journal of Immunology 159, 10128.[Abstract]
17 . Spengler, U., Kacsmarska, A., Grünerbl, A. et al. (1988). Involvement of immunological mechanism in the pathogenesis of non-A, non-B hepatitis. In Viral Hepatitis and Liver Disease: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease, May 2628, 1987 (Zuckerman, A. J., Ed.), pp. 5769. A. R. Liss, New York, USA.
18 . Samson, M., Libert, F., Doranz, B. J. et al. (1996). Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 7225.[CrossRef][ISI][Medline]
19 . Dragic, T., Litwin, V., Allaway, G. P. et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 66773.[CrossRef][ISI][Medline]
20
.
Dean, M., Carrington, M., Winkler, C. et al. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 185662.
21
.
Andres, P. G., Beck, P. L., Mizoguchi, E. et al. (2000). Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. Journal of Immunology 164, 630312.
22
.
Zhou, Y., Kurihara, T., Ryseck, R. P. et al. (1998). Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. Journal of Immunology 160, 401825.
23
.
Nguyen, G. T., Carrington, M., Beeler, J. A. et al. (1999). Phenotypic expressions of CCR5-32/
32 homozygosity. Journal of Acquired Immune Deficiency Syndromes 22, 7582.[ISI][Medline]
24
.
Woitas, R. P., Ahlenstiel, G., Iwan, A. et al. (2002). Frequency of the HIV-protective CC chemokine receptor 5-32/
32 genotype is increased in hepatitis C. Gastroenterology 122, 17218.[ISI][Medline]
25
.
Mangia, A., Santoro, R., DAgruma, L. et al. (2003). HCV chronic infection and CCR5-32/
32. Gastroenterology 124, 8689; author reply 86970.[CrossRef][ISI]
26 . Promrat, K., McDermott, D. H., Gonzalez, C. M. et al. (2003). Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124, 35260.[CrossRef][ISI][Medline]
27
.
Zhang, M., Goedert, J. J. & OBrien, T. R. (2003). High frequency of CCR5-32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 124, 8678.[CrossRef][ISI][Medline]
28 . Woitas, R. P., Ahlenstiel, G., Sauerbruch, T. et al. (2003). Reply. Gastroenterology 124, 15601.[ISI]
29 . Hellier, S., Frodsham, A. J., Hennig, B. J. et al. (2003). Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38, 146876.[ISI][Medline]
30 . Wald, O., Pappo, O., Ari, Z. B. et al. (2003). CCR5-D32 allele reduces liver inflammation and liver damage in early stages of HCV infection. Abstract presented at the Chemokines 2 Meeting, Paris, France, 2003.
31
.
Yang, Y. F., Tomura, M., Iwasaki, M. et al. (2001). IFN- acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. Journal of Clinical Immunology 21, 4029.[CrossRef][ISI][Medline]
32
.
Ning, Q., Brown, D., Parodo, J. et al. (1998). Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. Journal of Immunology 160, 348793.
33 . Tam, R. C., Pai, B., Bard, J. et al. (1999). Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. Journal of Hepatology 30, 37682.[CrossRef][ISI][Medline]
34
.
Ahlenstiel, G., Berg, T., Woitas, R. P. et al. (2003). Effects of the CCR5-32 mutation on antiviral treatment in chronic hepatitis C. Journal of Hepatology 39, 24552.[CrossRef][ISI][Medline]
35 . Dorak, M. T., Folayan, G. O., Niwas, S. et al. (2002). C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection. Immunologic Research 26, 16775.[CrossRef][ISI][Medline]
36
.
Glas, J., Torok, H. P., Simperl, C. et al. (2003). The 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-
and ribavirin. Clinical Immunology 108, 4650.[CrossRef][ISI][Medline]
37 . Garred, P., Madsen, H. O., Petersen, J. et al. (1998). CC chemokine receptor 5 polymorphism in rheumatoid arthritis. Journal of Rheumatology 25, 14625.[ISI][Medline]
38 . Zapico, I., Coto, E., Rodriguez, A. et al. (2000). CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes and Immunity 1, 2889.[CrossRef][ISI][Medline]
39 . Barcellos, L. F., Schito, A. M., Rimmler, J. B. et al. (2000). CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51, 2818.[CrossRef][ISI][Medline]
40
.
Sellebjerg, F., Madsen, H. O., Jensen, C. V. et al. (2000). CCR5 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. Journal of Neuroimmunology 102, 98106.[CrossRef][ISI][Medline]
41 . Fischereder, M., Luckow, B., Hocher, B. et al. (2001). CC chemokine receptor 5 and renal-transplant survival. Lancet 357, 175861.[CrossRef][ISI][Medline]
42
.
Hall, I. P., Wheatley, A., Christie, G. et al. (1999). Association of CCR5 32 with reduced risk of asthma. Lancet 354, 12645.[CrossRef][ISI][Medline]
43 . Mitchell, T. J., Walley, A. J., Pease, J. E. et al. (2000). Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 356, 14912.[CrossRef][ISI][Medline]
44
.
Petrek, M., Drabek, J., Kolek, V. et al. (2000). CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine 162, 10003.
45 . Aguilar, F., Nunez-Roldan, A., Torres, B. et al. (2003). Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. Journal of Rheumatology 30, 17704.[ISI][Medline]
46
.
Manes, S., Mira, E., Colomer, R. et al. (2003). CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. Journal of Experimental Medicine 198, 13819.
|